The goal of a study by Stahl [101] was to analyze men with de novo stage IV breast cancer and known estrogen receptor (ER) and progesterone receptor (PR) statuses who underwent systemic therapy, with or without surgery. The gene discussed is ESR1; the disease is breast cancer.